Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer?

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Markowska, Anna ^a   Pawałowska, Monika ^a   Filas, Violetta ^a   Korski, Konstanty ^a   Gryboś, Marian ^b   Sajdak, Stefan ^a   Olejek, Anita ^c   Bednarek, Wiesława ^d   Śpiewankiewicz, Beata ^e   Lubin, Jolanta ^a   Markowska, Janina ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d Lublin University of Natural Sciences   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Beta catenin; Diabetes; Endometrial cancer; ER; IGF 1; IGF 1R; Metformin; PAX 2; PR

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR; INSULIN; METFORMIN; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR PAX2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 84889022150     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-76     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer 2010 http://globocan.iarc.fr
2. Small is beautiful: Insulin-like growth factors and their role in growth, development and cancer. Maki RG, J Clin Oncol 2010 28 33 4985 4995 10.1200/JCO.2009.27.5040 20975071
3. The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells. Zhang G, Li X, Zhang L, Zhao L, Jiang J, Wang J, Wei L, Cancer Genet Cytogenet 2010 200 2 140 148 10.1016/j.cancergencyto.2010.04.007 20620597
4. Overexpression of the Insulin-Like Growth Factor I Receptor and Activation of the Akt Pathway in Hyperplastic Endometrium. McCampbell A, Broaddus R, Loose D, Davies PJ, Clin Cancer Res 2006 12 6373 6378 10.1158/1078-0432.CCR-06-0912 17085648 (Pubitemid 44799707)
5. Metformin and reduced risk of cancer in diabetic patients. Evans J, Donnelly L, Emslie-Smith AM, Alessi DR, Morris AD, BMJ 2005 330 1304 1305 10.1136/bmj.38415.708634.F7 15849206 (Pubitemid 40813563)
6. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Bowker S, Majumdar S, Veugelers P, Johnson JA, Diabetes Care 2006 29 254 258 10.2337/diacare.29.02.06.dc05-1558 16443869 (Pubitemid 44106500)
7. Metformin and cancer risk in diabetic patients. A systemic review and meta-analysis. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S, Cancer Prev Res 2010 3 1451 1461 10.1158/1940-6207.CAPR-10-0157
8. Metformin and incident breast cancer among diabetic women: A population-based control-case study in Denmark. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL, Cancer Epidemiol Biomarkers Prev 2011 20 101 111 10.1158/1055-9965.EPI-10-0817 21119073
9. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL, Gynecol Oncol 2010 116 1 92 98 10.1016/j.ygyno.2009.09.024 19822355
10. AMPK in health and disease. Steinberg GR, Kemp B, Physiol Rev 2009 89 1025 1078 10.1152/physrev.00011.2008 19584320
11. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M, Cancer Res 2006 66 10269 10273 10.1158/0008-5472.CAN-06-1500 17062558 (Pubitemid 44799743)
12. Function of Akt/PKB signaling to cell molility, invasion and tumor stroma cancer. Chin YR, Tokr A, Cell Signal 2009 21 470 476 10.1016/j.cellsig.2008.11. 015 19110052
13. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Ouban A, Muraca P, Yeatman T, Coppola D, Hum Pathol 2003 34 803 808 10.1016/S0046-8177(03)00291-0 14506643 (Pubitemid 37040618)
14. Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Boone DN, Lee AV, Crit Rev Oncol 2012 17 2 161 173 10.1615/CritRevOncog.v17.i2.30
15. Abnormalities of E and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. Moreno-Bueno G, Hardisson D, Sarrio D, Sánchez C, Cassia R, Prat J, Herman JG, Esteller M, Matías-Guiu X, Palacios J, J Pathol 2003 199 471 478 10.1002/path.1310 12635138 (Pubitemid 36411224)
16. Suppression of E-cadherin and alpha- and beta-catenin mRNA expression in the metastatic lesions of gynecological cancers. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T, Eur J Gynaecol Oncol 1997 18 484 487 9443016 (Pubitemid 27519415)
17. PAX genes in cancer; friends or foes? Li CG, Eccles MR, Front Genet 2012 3 6 1 7 22303408
18. PAX genes: roles in development, pathophysiology and cancer. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA, Biochem Pharmacol 2007 73 1 1 14 10.1016/j.bcp.2006.06.024 16904651 (Pubitemid 44868976)
19. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ, Am J Surg Pathol 2010 34 2 137 146 10.1097/PAS.0b013e3181c89c98 20061933
20. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL, Cancer Res 2010 70 15 6225 6232 10.1158/0008-5472.CAN-10-0149 20631067
21. The paired homeodomain transcription factor PAX2 is expressed in the endocrine pancreas and transactivates the glucagon gene promoter. Ritz-Laser B, Estreicher A, Gauthier B, Philippe J, J Biol Chem 2000 275 42 32708 32715 10938089
22. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Harvey JM, Clark GM, Osborne CK, Allred DC, J Clin Oncol 1999 17 5 1474 1481 10334533 (Pubitemid 29220854)
23. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Friberg E, Orsini N, Mantzoros CS, Wolk A, Diabetologia 2007 50 1365 1374 10.1007/s00125-007-0681-5 17476474 (Pubitemid 46879010)
24. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD, Cancer Epidemiol Biomarkers Prev 2008 17 4 921 929 10.1158/1055-9965.EPI-07-2686 18398032 (Pubitemid 351536424)
25. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Cust AE, Allen NE, Rinaldi S, et al. Int J Cancer 2007 120 2656 2664 10.1002/ijc.22578 17285578 (Pubitemid 46651288)
26. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D, Eur J Gynaecol Oncol 2001 22 2 122 126 11446475 (Pubitemid 32963063)
27. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Jongen V, Briet J, De Jong R, Ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H, Gynecol Oncol 2009 112 3 537 542 10.1016/j.ygyno.2008.10. 032 19108875
28. Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. Zhou J, Dsupin BA, Giudice LC, Bondy CA, J Clin Endocrinol Metab 1994 79 1723 1734 10.1210/jc.79.6.1723 7527408
29. Ligand-independent Activation of Steroid Receptors: New Roles for Old Players. Cenni B, Picard D, Trends Endocrinol Metab 1999 10 2 41 46 10.1016/S1043-2760(98)00121-0 10322393 (Pubitemid 29287821)
30. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Kleinman D, Karas M, Roberts CT Jr, et al. Endocrinology 1995 136 6 2531 2537 10.1210/en.136.6.2531 7750475
31. p53 regulates insulin-like growth factor- I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, Bruchim I, Werner H, Eur J Cancer 2012 48 10 1570 1580 10.1016/j.ejca.2011.09.014 22033326
32. Gene expression profiles in normal and cancer cells. Zhang L, Zhou W, Velculescu VE, et al. Science 1997 276 1268 1272 10.1126/science.276.5316.1268 9157888 (Pubitemid 27227367)
33. Expression of the type 1 insulinlike growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM, Cancer Res 2002 62 2942 2950 12019176 (Pubitemid 34525783)
34. Insulin-Like Growth Factors, Insulin-Like Growth Factor-Binding Proteins, and Endometrial Cancer in Postmenopausal Women: Results from a U.S. Case-control Study. Lacey JV Jr, Potischman N, Madigan MP, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR, Fillmore CM, Sherman ME, Brinton LA, Cancer Epidemiol Biomarkers Prev 2004 13 4 607 612 15066926 (Pubitemid 38737897)
35. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. Lathi RB, Hess AP, Tulac S, Nayak NR, Conti M, Giudice LC, J Clin Endocrinol Metab 2005 90 1599 1606 15613433 (Pubitemid 40464025)
36. Prognostic significance of hormone receptors in endometrial cancer. Creasman WT, Cancer 1993 71 1467 1470 10.1002/cncr.2820710411 8431882 (Pubitemid 23056062)
37. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. Xie Y, Wang Y, Tu L, Hu Q, Ji L, Zhang Y, Liao QP, J Steroid Biochem Mol Biol 2011 126 113 120 10.1016/j.jsbmb.2010.12.006 21168492
38. More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin. Bernstein LM, Boyarkina MP, Tsyrlina EV, Turkevich EA, Semiglazov VF, Med Oncol 2010 6 1313 1323
39. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Brown K, Hunger N, Docanto M, Simpson ER, Breast Cancer Res Treat 2010 123 591 596 10.1007/s10549-010-0834-y 20300828
40. Expression of IGF-1R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial adenocarcinoma. Pengchong H, Tao H, Eur J Gynaecol Oncol 2011 32 6 660 664 22335030
41. Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. Roy RN, Gerulath AH, Cecutti A, Bhavnani BR, Mol Cell Endocrinol 1999 153 19 27 10.1016/S0303-7207(99)00092-1 10459850 (Pubitemid 29339153)
42. beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Saegusa M, Hashimura M, Yoshida T, Okayasu I, Br J Cancer 2001 84 2 209 217 10.1054/bjoc.2000.1581 11161379 (Pubitemid 32113448)
43. The expression of Wnt4 is regulated by estrogen via an estrogen receptor alpha-dependent pathway in rat pituitary growth hormone-producing cells. Miyakoshi T, Kajiya H, Miyajima K, Takei M, Tobita M, Takekoshi S, Osamura RY, Acta Histochem Cytochem 2009 42 205 213 10.1267/ahc.09033 20126574
44. Estrogens modulate the gene expression of Wnt-7a in cultured endometrial adenocarcinoma cells. Wagner J, Lehmann L, Mol Nutr Food Res 2006 50 368 372 10.1002/mnfr.200500215 16534752
45. Interaction of estrogen receptors with insulin-like growth factor-I and Wnt signaling in the nervous system. Varea O, Arevalo MA, Garrido JJ, Garcia-Segura LM, Wandosell F, Mendez P, Steroids 2010 75 565 569 10.1016/j.steroids.2009.09.006 19778547
46. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, García- Rostán G, Jaime P, Guo M, Herman JG, Matías-Guiu X, Esteller M, Palacios J, Oncogene 2002 21 7981 7990 10.1038/sj.onc.1205924 12439748 (Pubitemid 35430609)
47. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. Konopka B, Janiec-Jankowska A, Czapczak D, Paszko Z, Bidziński M, Olszewski W, Goluda C, J Cancer Res Clin Oncol 2007 133 361 371 10.1007/s00432-006-0179-4 17219201 (Pubitemid 46716700)
48. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-Akt, Wnt/β-catenin and P53 pathway activation. Nout R, Bosse T, Creutzberg C, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Van Eijk R, Ter Haar NT, Smit VT, Gynecol Oncol 2012 126 466 473 10.1016/j.ygyno.2012.05.012 22609107
49. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. Allison KH, Upson K, Reed SD, Jordan CD, Newton KM, Doherty J, Swisher EM, Garcia RL, Int J Gynecol Pathol 2012 31 2 151 159 22317873